WO2012061910A3 - Main immunoprotective domains and epitopes of nucleoside hydrolase from leishmania (l) donovani for use in vaccination, immunotherapy and diagnosis - Google Patents

Main immunoprotective domains and epitopes of nucleoside hydrolase from leishmania (l) donovani for use in vaccination, immunotherapy and diagnosis Download PDF

Info

Publication number
WO2012061910A3
WO2012061910A3 PCT/BR2011/000411 BR2011000411W WO2012061910A3 WO 2012061910 A3 WO2012061910 A3 WO 2012061910A3 BR 2011000411 W BR2011000411 W BR 2011000411W WO 2012061910 A3 WO2012061910 A3 WO 2012061910A3
Authority
WO
WIPO (PCT)
Prior art keywords
main
donovani
leishmania
epitopes
immunoprotective
Prior art date
Application number
PCT/BR2011/000411
Other languages
French (fr)
Portuguese (pt)
Other versions
WO2012061910A2 (en
Inventor
Clarisa Beatriz Palatnik De Souza
Maurício MARTINS RODRIGUES
Irene Da Silva Soares
Marcos Palatnik
Nico Dirlei
Original Assignee
Universidade Federal Do Rio De Janeiro
Universidade Federal De São Paulo
Universidade De São Paulo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidade Federal Do Rio De Janeiro, Universidade Federal De São Paulo, Universidade De São Paulo filed Critical Universidade Federal Do Rio De Janeiro
Priority to PCT/BR2011/000411 priority Critical patent/WO2012061910A2/en
Publication of WO2012061910A2 publication Critical patent/WO2012061910A2/en
Publication of WO2012061910A3 publication Critical patent/WO2012061910A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2497—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing N- glycosyl compounds (3.2.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

The present innovation relates to the identification of the main sequences of the protein nucleoside hydrolase from Leishmania (L) donovani, to be included in a recombinant, DNA or synthetic vaccine to protect and cross-protect against leishmanioses. It also relates to the identification of the main epitopes that react with antibodies to be used in the immunodiagnosis of leishmanioses, and to the use thereof to give cross-protection against other micro-organisms having a sequence in common in the nucleoside hydrolases thereof.
PCT/BR2011/000411 2010-11-08 2011-11-08 Main immunoprotective domains and epitopes of nucleoside hydrolase from leishmania (l) donovani for use in vaccination, immunotherapy and diagnosis WO2012061910A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/BR2011/000411 WO2012061910A2 (en) 2010-11-08 2011-11-08 Main immunoprotective domains and epitopes of nucleoside hydrolase from leishmania (l) donovani for use in vaccination, immunotherapy and diagnosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR020100104068 2010-11-08
PCT/BR2011/000411 WO2012061910A2 (en) 2010-11-08 2011-11-08 Main immunoprotective domains and epitopes of nucleoside hydrolase from leishmania (l) donovani for use in vaccination, immunotherapy and diagnosis

Publications (2)

Publication Number Publication Date
WO2012061910A2 WO2012061910A2 (en) 2012-05-18
WO2012061910A3 true WO2012061910A3 (en) 2012-09-13

Family

ID=46051339

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2011/000411 WO2012061910A2 (en) 2010-11-08 2011-11-08 Main immunoprotective domains and epitopes of nucleoside hydrolase from leishmania (l) donovani for use in vaccination, immunotherapy and diagnosis

Country Status (1)

Country Link
WO (1) WO2012061910A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023077206A1 (en) * 2021-11-08 2023-05-11 Universidade Federal Do Rio De Janeiro - Ufrj Genetically modified epitopes and multiepitope proteins, immunogenic compositions and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0503187A (en) * 2005-05-16 2007-01-23 Univ Rio De Janeiro a composition comprising fractions or sub-fractions of leishmania promastigotes or amastigotes called fucose mannose ligand (fml) and saponin, a composition for preparing leishmaniasis transmission blocking vaccines in humans and animals comprising fractions or sub-fractions of leishmania promastigotes or amastigotes (fml) ) and saponin, use of the composition in the preparation of blocking vaccines to prevent the transmission of human or animal visceral leishmaniasis, use of the composition in the preparation of reagents consisting of administration of fractions or sub-fractions of leishmania promastigotes or amastigotes called fucose mannose ligand ( fml) and saponin
WO2011006219A1 (en) * 2009-07-13 2011-01-20 Universidade Federal Do Rio De Janeiro Process and composition for treatment of canine and human leishmaniasis
WO2012064659A1 (en) * 2010-11-08 2012-05-18 Infectious Disease Research Institute Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0503187A (en) * 2005-05-16 2007-01-23 Univ Rio De Janeiro a composition comprising fractions or sub-fractions of leishmania promastigotes or amastigotes called fucose mannose ligand (fml) and saponin, a composition for preparing leishmaniasis transmission blocking vaccines in humans and animals comprising fractions or sub-fractions of leishmania promastigotes or amastigotes (fml) ) and saponin, use of the composition in the preparation of blocking vaccines to prevent the transmission of human or animal visceral leishmaniasis, use of the composition in the preparation of reagents consisting of administration of fractions or sub-fractions of leishmania promastigotes or amastigotes called fucose mannose ligand ( fml) and saponin
WO2011006219A1 (en) * 2009-07-13 2011-01-20 Universidade Federal Do Rio De Janeiro Process and composition for treatment of canine and human leishmaniasis
BRPI0902443A2 (en) * 2009-07-13 2011-03-15 Univ Rio De Janeiro immunochemotherapeutic process and pharmaceutical composition for treatment of canine and human leishmaniasis
WO2012064659A1 (en) * 2010-11-08 2012-05-18 Infectious Disease Research Institute Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AGUILAR-BE I ET AL.: "Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis.", INFECTION AND IMMUNITY, vol. 73, no. 2, February 2005 (2005-02-01), pages 812 - 819 *
CUI L ET AL.: "A nonspecific nucleoside hydrolase from Leishmania donovani: implications for purine salvage by the parasite.", GENE, vol. 280, no. 1-2, pages 153 - 162 *
DATABASE GENBANK 14 December 2001 (2001-12-14), "nonspecific nucleoside hydrolase [Leishmania donovani]", accession no. AK57552.1. *
DATABASE GENBANK 9 January 2006 (2006-01-09), "inosine-uridine preferring nucleoside hydrolase [Leishmania infantum]", accession no. AF05936.1. *
GAMBOA-LEON R ET AL.: "Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani", VACCCINE, vol. 24, no. 22, 29 May 2006 (2006-05-29), pages 4863 - 4873 *
NICO, D ET AL.: "Adaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective response.", PLOS NEGLECTD TROPICAL DISEASES, vol. 4, no. 11, pages E866 *
NICO, D ET AL.: "Cloning of the Nucleoside hydrolase of Leishmania donovani aiming at the development of a synthetic vaccine against visceral leishmaniasis.", PROCEDIA IN VACCINOLOGY, vol. 1, 20 September 2009 (2009-09-20), pages 115 - 119, Retrieved from the Internet <URL:http://dx.doi/10.1016/j.provac.2009.07.021> *
NICO, D.: "Desenvolvimento de uma vacina sintetiva contra a Leishmaniose visceral a partir da nucleosídeo hidrolase Leishmania (L.) donovani.", THESIS ON DOCTORATE, July 2010 (2010-07-01), RIO DE JANEIRO, pages 120 *
PALATNIK-DE-SOUZA CB ET AL.: "FML vaccine against canine visceral leishmaniasis: from second-generation to synthetic vaccine.", EXPERT REV VACCINES, vol. 7, no. 6, August 2008 (2008-08-01), pages 833 - 851 *

Also Published As

Publication number Publication date
WO2012061910A2 (en) 2012-05-18

Similar Documents

Publication Publication Date Title
WO2014009438A3 (en) Mycobacterial antigen vaccine
CU20120095A7 (en) PCSK9 ANTAGONISTS
EP3563865A3 (en) Prostate-associated antigens and vaccine-based immunotherapy regimens
TN2012000167A1 (en) Human il-23 antigen binding proteins
NZ602220A (en) Antibodies with ph dependent antigen binding
WO2016176624A3 (en) Porcine pestvirus, vaccines, and assays
WO2008059252A3 (en) Methods and composition fro t cell receptors which recognize 5t4 antigen
DOP2013000029A (en) PEPTIDIC ANTIBODIES BETA AMILOIDE ANTI-N3PGLU AND USES OF THE SAME
IL232219B (en) Human or humanized anti-tar-dna-binding protein 43kda antibodies and uses thereof
WO2012009644A3 (en) Methods to identify synthetic and natural rna elements that enhance protein translation
MX348071B (en) Fc variants.
WO2013040142A3 (en) Bioinformatic processes for determination of peptide binding
NZ702145A (en) Bluetongue virus recombinant vaccines and uses thereof
EP2542581A4 (en) Antibody specific for apolipoprotein and methods of use thereof
MX2014000054A (en) Anti-alpha synuclein binding molecules.
WO2008005880A3 (en) Antibodies for norovirus
EA200701911A1 (en) CHEMERIC RECOMBINANT ANTIGENS OF TOXOPLASMA GONDII
EA201390676A1 (en) VACCINES CONTAINING NON-SPECIFIC NUCLEOSIDE HYDROLASE POLYPEPTIDES AND STEROL 24-C-Methyltransferase (SMT), for the treatment and diagnosis of leishmaniasis
WO2011090708A3 (en) Recombinant ndv antigen and uses thereof
AR080585A1 (en) VACCINATION AGAINST TUMORS UNDERSTANDING AN IMMUNE HUMORAL RESPONSE AGAINST OWN PROTEINS
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
WO2009114085A3 (en) Allogeneic cancer cell-based immunotherapy
MX353464B (en) Soluble immunoreactive treponema pallidum tpn47 antigens.
EA200970731A1 (en) HUMAN CYTOMEGALOVIRUS RECOMBINANT ANTIGENS (HCMV)
EP2528939A4 (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11840259

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11840259

Country of ref document: EP

Kind code of ref document: A2